Scientific Funder & Advisor
Dr. Jie Xu, the
founder of BioTroy
Therapeutics,
is a senior
researcher in the
field of oncology. He has long been committed to the discovery of new targets
for tumor immunotherapy and the development of related drugs, he already discovered
new immune checkpoints such as CD3L1 and Galectin-8, related research results
have been published in Cell and other international top journals. A new anti-tumor drug (first-in-class) developed from the breakthrough
scientific discovery of CD3L1
target has been in clinical development, after obtained the IND approval from
FDA and China NMPA.
Selected publications:
1. ITPRIPL1 binds CD3ε to impede
T-cell activation and enable tumor immune evasion. Cell, 2024 Apr
5:S0092-8674(24)00310-62. Discovery of galectin-8 as an
LILRB4 ligand driving M-MDSCs defines a class of antibodies to fight solid
tumors. Cell Reports Medicine, 2024,5(1):1013743. HIP1R targets PD-L1 to lysosomal
degradation to alter T cell-mediated cytotoxicity. Nature Chemical
Biology, 2019 (1): 42~50. 4. Inhibiting PD-L1 palmitoylation
enhances T-cell immune responses against tumours, Nature Biomedical
Engineering，2019; 3(5):414.5. A Designed Peptide Targets Two
Types of Modifications of p53 with Anti-cancer Activity, Cell Chemical
Biology, 2018, 25(6): 761~774
Book Editor:
《Regulation
of Cancer Immune Checkpoints》 Springer Book. 2020 ISBN: 9811532656
Scientific awards
The Leading Talent, ‘‘10000 Plan’’ of China
Top-Notch Young Talents, ‘‘10000 Plan’’ of China
